Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014461 | 0.91 | EPHX1 (0.43) | EPHX1TP53SIGMAR1KDM4EGMNN | |
| SCHEMBL12322284 | 0.89 | EPHX1 (0.39) | EPHX1TP53SIGMAR1KDM4EGMNN | |
| SCHEMBL22839344 | 0.89 | EPHX1 (0.39) | EPHX1TP53SIGMAR1KDM4EGMNN | |
| SCHEMBL9376499 | 0.85 | SIGMAR1 (0.42) | EPHX1TP53SIGMAR1KDM4EGMNN | |
| SCHEMBL20042193 | 0.83 | SIGMAR1 (0.45) | EPHX1TP53SIGMAR1KDM4EGMNN | |
| SCHEMBL26460968 | 0.78 | EPHX1 (0.46) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL22921029 | 0.78 | EPHX1 (0.46) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL6062805 | 0.78 | EPHX1 (0.46) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL20145288 | 0.77 | SIGMAR1 (0.38) | EPHX1SIGMAR1LMNABLMCPB2 | |
| SCHEMBL10729418 | 0.76 | EPHX1 (0.42) | EPHX1TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | EPHX1 2660/4885TP53 23/4885SIGMAR1 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.